Role of histopathology and molecular markers in the active surveillance of prostate cancer

Acta Oncologica

Volumn 50, Issue SUPPL. 1, 2011, Pages 56-60

  Montironi, Rodolfo ^a   Egevad, Lars ^b   Bjartell, Anders ^c   Berney, Daniel M ^d  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MEDLINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3; PROSTATECTOMY; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; TUMOR GENE;

DISEASE PROGRESSION; HUMANS; MALE; MONITORING, PHYSIOLOGIC; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79957474926     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.522199     Document Type: Review

References (27)

1. Dall 'E ra MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, et al. Active surveillance for early-stage prostate cancer: Review of the current literature. Cancer, 2008, 112, 1650-9. (Pubitemid 351536825)
2. Johansson JE, Adami HO, Andersson SO, Bergströ m R, Krusemo UB, Kraaz W. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients. Lancet 1989;1(8642):799-803. (Pubitemid 19103127)
3. Bill-Axelson A, Holmberg L, Ruutu M, Hä g gman M, Andersson SO, Bratell S. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977-84.
4. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical fi ndings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74. (Pubitemid 24037911)
5. D 'A mico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specifi c survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002;20:4567-73. (Pubitemid 35402960)
6. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred defi nitive therapy. J Urol 2004;171:1520-4. (Pubitemid 38365409)
7. Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M. Active surveillance; a reasonable management alternative for patients with prostate cancer: The Miami experience. BJU Int 2008;101:165-9. (Pubitemid 350294039)
8. Van As NJ, Norman AR, Thomas K, Khoo VS, Thompson A, Huddart RA, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol 2008;54:1297-305.
9. Van den Bergh RCN, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH. Prospective validation of active surveillance in prostate cancer: The PRIAS study. Eur Urol 2007;52:1560-3. (Pubitemid 350052404)
10. Ploussard G, Xylinas E, Salomon L, Allory Y, Vordos D, Hoznek A, et al. The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol 2009;56:891-8.
11. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: Preliminary results. J Urol 2002;167:1231-4. (Pubitemid 34132060)
12. Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, et al. Expectant management of prostate cancer with curative intent: An update of the Johns Hopkins experience. J Urol 2007;178:2359-64.
13. Dall 'E ra MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008, 112, 2664-70. (Pubitemid 351969209)
14. Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int 2005;95:956-60. (Pubitemid 40655686)
15. Klotz L. Active surveillance for prostate cancer: For whom? J Clin Oncol 2005;23:8165-9. (Pubitemid 46211550)
16. Klotz L. Active surveillance with selective delayed intervention is the way to manage " good-risk " prostate cancer. Nat Clin Pract Urol 2005;2:136-42. (Pubitemid 40812444)
17. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol 2006;24:46-50. (Pubitemid 43097357)
18. Ercole B, Marietti SR, Fine J, Albertsen PC. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specifi c antigen era. J Urol 2008;180:1336-9.
19. Roemeling S, Roobol MJ, de Vries SH, Wolters T, Gosselaar C, van Leenders GJ, et al. Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: Characteristics, PSA doubling times, and outcome. Eur Urol 2007;51:1244-51. (Pubitemid 46436308)
20. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983;301:89-92. (Pubitemid 13154475)
21. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-7. (Pubitemid 24356419)
22. Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostatespecifi c antigen recurrence following radical prostatectomy. Clin Cancer Res 2005;11:4037-43. (Pubitemid 40791567)
23. Demichelis F, Fall K, Perner S, Andr é n O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-9.
24. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008;54:1081-8.
25. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance. J Urol 2008;179:1804-9.
26. Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010;183:534-8.
27. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, et al. Insignifi cant prostate cancer and active surveillance: From defi nition to clinical implications. Eur Urol 2009;55:1321-30.